Differences in cyclin B1 expression in cells blocked in the G2M phase after treatment with anticancer agent. New three-parametric flow cytometric analysis.
Faretta
M
M
Flow Cytometry Unit, Mario Negri Institute, Milan, Italy.
Bergamaschi
D
D
Ronzoni
S
S
D'Incalci
M
M
Erba
E
E
D000970:Antineoplastic Agents / Q000494:pharmacology*; D002453:Cell Cycle / Q000187:drug effects; D019926:Cyclin B / Q000378:metabolism*; D056744:Cyclin B1; D004214:Distamycins / Q000494:pharmacology*; D005434:Flow Cytometry; D016195:G2 Phase / Q000187:drug effects*; D006801:Humans; D019169:Jurkat Cells; D008938:Mitosis / Q000187:drug effects*; D009588:Nitrogen Mustard Compounds / Q000494:pharmacology*; D013997:Time Factors
D000970:Antineoplastic Agents; C534699:CCNB1 protein, human; D019926:Cyclin B; D056744:Cyclin B1; D004214:Distamycins; D009588:Nitrogen Mustard Compounds; C066900:tallimustine